PTEN and neoplasm: The combination had broad activity, with increased tumour regression compared to either of the monotherapies, seen in PTEN null (PAC120, HID28, and C4-2), and PTEN WT (CTG-2428 and VCAP) models (Fig. 1a, b, c, d, f, g, h, Supplementary Fig. 1).